|
|
Article: Gilead Sciences Announces Completion of European Application to Market VISTIDE for CMV Retinitis.
- Article from:
- Business Wire
- Article date:
- January 23, 1996
CopyrightCOPYRIGHT 1996 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FOSTER CITY, Calif.--(HealthWire)--Jan. 23, 1996--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the European Medicines Evaluation Agency (EMEA) has accepted the Company's application for authorization to market VISTIDE(TM) (cidofovir intravenous) for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. This application, submitted December 1995, was accepted under the European Community centralized licensing procedure, which provides for authorization of human therapeutic products for marketing in all member states of the European Community. Review of the application will be coordinated by the EMEA, with regulatory authorities from Portugal and ...
Related newspaper, magazine, and journal articles:
|
|
Article: Antiretroviral therapy helps CMV retinitis in AIDS ...
Ophthalmology Times;
June 15, 2000 ;
700+ words
... ... patient has stable CMV retinitis and evidence of immune ... Dr. Kupfer said. CMV retinitis occurred in about 40 ... said. Standard anti-CMV retinitis treatment with systemic ... cidofovir (Vistide, Gilead Sciences), or an intravitreal ...
|
|